Abstract
The long-term effects of two schedules of radioiodine therapy in patients with toxic multinodular goitre were evaluated. Forty-five patients (group A) were treated with low doses and 58 patients (group B) with calculated doses adjusted for thyroid weight (1.85–3.70 MBq/g) and radioactive iodine uptake. Follow-up (mean ± SEM) was 4.3 ± 0.2 years and 5.2 ± 0.3 years, respectively (P>0.1). At the end of follow-up, hyperthyroidism was successfully reversed in 73% (group A) and 88% (group B). In each group, hypothyroidism was present in 7%. The total dose per gram of thyroid tissue was not significantly different in groups A and B (2.1 ± 0.2 vs 2.7 ± 0.2 MBq/g). However, for patients treated with calculated doses the number of 131I administrations was significantly lower (1.3 ± 0.1) than for patients treated with low doses (2.2 ± 0.2), and the percentage of patients who were adequately treated with a single dose was more than twice as high (66% in group B versus 27% in group A). Euthyroidism was reached within a significantly shorter time after treatment with calculated doses (median time 0.6 years in group B vs 1.5 years in group A; life table analysis). It is concluded that radioiodine is an effective treatment for toxic multinodular goitre with a low risk of post-treatment hypothyroidism and that calculated (higher) doses appear to be preferable to low doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sridama V, McCormick M, Kaplan EL, Faucher R, DeGroot LJ. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med 1984;311: 426–432
Goolden AWG, Stewart JSW. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol 1986;24: 217–222
Seed L, Jaffé B. Results of treatment of toxic goiter with radioactive iodine. J Clin Endocrinol 1953;13: 107–119
Eller M, Silver S, Yohalem S, Segal R. The treatment of toxic nodular goiter with radioactive iodine: 10 years' experience with 436 cases. Ann Intern Med 1960;52: 976–1013
Lamberg B, Hernberg C, Wahlberg P, Hakkila R. Treatment of toxic nodular goitre with radioactive iodine. Acta Med Scand 1959;165:245–258
Dunn J, Chapman E. Rising incidence of hypothyroidism after radioactive-iodine therapy in thyrotoxicosis. N Engl J Med 1964;271: 1037–1042
Nofal M, Beierwaltes W, Patno M. Treatment of hyperthyroidism with sodium iodide I 131. JAMA 1966;197: 605–610
Viherkoski M, Lamberg B, Hernberg C, Niemi E. Treatment of toxic nodular and diffuse goitre with radioactive iodine. Acta Endocrinol (Copenh) 1970;64: 159–170
Glanzmann C, Kaestner F, Horst W. Therapie der Hyperthyreose mit Radio-Isotopen des Jods: Erfahrungen bei über 2000 Patienten. Klin Wochenschr 1975;53: 669–678
Heinze HG, Schenk F. 131J-Therapie der Hyperthyreose. Nuklearmedizin 1977;16: 1–12
Bliddal H, Hansen JM, Rogowski P, Johansen K, Friis T, Siersbaek-Nielsen K. 131I treatment of diffuse and nodular toxic goitre with or without antithyroid agents. Acta Endocrinol (Copenh) 1982;99: 517–521
Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982;23: 103–107
Hoeschel M, Heinze HG. 131J-Therapie des Morbus Basedow und der nicht-immunogenen Hyperthyreose. Nuklearmedizin 1984;23: 143–149
Wiener JD. Long-term follow-up after iodine-131 treatment for Plummer's disease (autonomous goitre). Clin Nucl Med 1985;10: 256–259
Jensen M, Gharib H, Naessens J, Heerden van J, Mayberry E. Treatment of toxic multinodular goitre (Plummer's disease): surgery or radioiodine? World J Surg 1986;10: 673–680
Moser E, Pickardt CR, Mann K, et al. Ergebnisse der Radiojod-Behandlung von Patienten mit immunogener und nichtimmunogener Hyperthyreose bei Anwendung unterschiedlicher Herddosen. Nuklearmedizin 1988;27: 98–104
Danaci M, Feek CM, Notghi A, Merrick MV, Padfield PL, Edwards CRW. 131I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre. NZ Med J 1988;101: 784–786
Kinser JA, Roesler H, Furrer T, Grütter D, Zimmermann H. Nonimmunogenic hyperthyroidism: cumulative hypothyroidism incidence after radioiodine and surgical treatment. J Nucl Med 1989;30: 1960–1965
Veneman TF, Weymer M, Tjabbes T, Haeften van TW. Relevance of cause of hyperthyroidism in determining its management. Neth J Med 1989;35: 303–308
Berding G, Schicha H. Ergebnisse der Radiojodtherapie der manifesten Hyperthyreose und der autonomen Struma mit Euthyreose. Nuklearmedizin 1990;29: 158–165
DeGroot LJ. Graves' disease diagnosis and treatment. Multinodular goiter. In: DeGroot LJ, Stanbury JB, eds. The thyroid and its diseases, 4th edition. New York: Wiley; 1975: 314–367,637–665
Doering P Gewichtsbestimmung der menschlichen Schilddrüse mit der Szintigraphie. Klin Wochenschr 1957;35: 944
SAS (Statistical Analyzing System) user's guide: statistics, version 5 edition. Cary, NC 27511-8000: SAS Institute Inc.; 1985
Huysmans D, Corstens F, Kloppenborg P. Long-term follow-up in toxic solitary autonomous thyroid nodules treated with radioactive iodine. J Nucl Med 1991;32: 27–30
Studer H, Gerber H. Toxic multinodular goiter. In: Braverman L, Utiger R, eds. Werner und Ingbar's the thyroid, 6th ed. Philadelphia: Lippincott; 1991: 692
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huysmans, D.A.K.C., Hermus, A.R.M.M., Corstens, F.H.M. et al. Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre. Eur J Nucl Med 20, 1056–1062 (1993). https://doi.org/10.1007/BF00173483
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00173483